CTAi The use of artificial intelligence (AI) in clinical trials is rapidly gaining momentum, as researchers and pharmaceutical companies alike recognize the potential of this technology to revolutionize the drug development process. One of the key benefits of AI is its ability to process large amounts of data quickly and efficiently…

Australia made history on July 1, 2023, when it became the first country in the world to prescribe MDMA and psilocybin for therapeutic use. The Therapeutic Goods Administration (TGA), Australia’s medicines regulator, approved the use of MDMA for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression. …

According to a new study from Research and Markets, the global market for AI-based clinical trial solutions for patient matching is expected to reach USD$1,969 million by 2030. This growth is fueled by sustained and increased investment in AI-based technologies to deliver higher efficiency and improve operational processes in clinical…

It takes up to 15 years and an average total R&D expenditure of $1.5–2 billion USD to bring a single new drug to market. About half of this investment is spent on clinical trials, with Phase III trials being the most complex and most expensive. Probabilities of success for compounds…

Over the past few weeks we have been meeting internally to define our strategy and goals in the runup to the new year. To this end we published the outline of our 2023 updated roadmap on the ClinTex homepage. Allow us a moment to briefly dive a little deeper into…

Clintex are excited to announce the signing of an agreement with LVL Health (https://lvlhealth.co.uk/) to support their CANPAIN clinical trial (https://clinicaltrials.gov/ct2/show/NCT05288010) evaluating Cannabis Based Medicinal Products (CBMPs) in the treatment of Chronic Pain. This clinical trial is particularly high profile as it is being conducted to provide key data to…

The autumnal months have begun to set in here in Europe as the crypto bear market drags on, mirroring the wider global macro economic uncertainty that has been so evident thus far in 2022. To say it has been a tumultuous year so far would be an understatement, however here…

We are extremely excited to announce that ClinTex are currently in active discussions with two ground breaking companies, to support clinical trials in the application of medicinal cannabis to manage chronic pain. Celadon Pharmaceuticals recently released a substantial business update since announcing to become the first British cannabis company since…

Since 2018, when the UK Home Office announced that cannabis-based medicinal products (CBMPs) were to be moved from Schedule 1 to Schedule 2 status in the misuse of drugs regulations, ClinTex have been closely monitoring associated clinical trials which can help prove that these compounds possess untapped medical utility. One…